Last year, 50% all new novel Food and Drug Administration drug approvals came from companies with a footprint in New Jersey, according to BioNJ.
The Trenton-based life sciences trade organization said it will be honoring the 24 companies with an Innovator Award at its 27th Annual Dinner Meeting & Innovation Celebration on Feb. 6 at the Hilton East Brunswick.
- Allergan for its drug Ubrelvy;
- Amgen for Evenity;
- Bayer Healthcare for Nubeqa;
- Beigene USA for Brukinsa;
- Bristol-Myers Squibb for Inrebic and Reblozyl;
- Daiichi Sankyo Inc. for Enhertu and Turalio;
- Eisai Inc. for Dayvigo;
- Eli Lilly for Reyvow;
- Galderma Research and Development for Aklief;
- Janssen Biotech for Balversa;
- Jazz Pharmaceuticals for Sunosi;
- Kyowa Kirin for Nourianz;
- Merck & Co. for Recarbrio;
- Novartis for Adakveo, Beovu, Piqray, Mayzent and Egaten;
- Pfizer for Vyndaqel;
- Sanofi for Cablivi;
- Shionogi & Co. for Fetroja;
- SK Life Science for Xcopri.
“We are so proud of New Jersey’s robust life sciences ecosystem which is responsible for exactly half of all of the 2019 novel innovations now making their way to Patients with cancer, Parkinson’s disease, heart disease, multiple sclerosis and more, reinforcing the fact that the Garden State is the drug development capital of the world,” BioNJ CEO and President Debbie Hart said. “Our Members are helping Patients live longer, better lives while lessening the burden of illness and disease on society. We are pleased to celebrate their important work and dedication in this way.”
The event will also include the presentation of the 13th annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to Kenneth C. Frazier, chairman of the board and CEO of Merck; and the Third Annual Heart of BioNJ Award to Mary Frances Harmon, senior vice president, corporate relations, PTC Therapeutics and Bob Tufts, founder, My Life Is Worth It.